#1 Clinical Trials Search in Europe

Human Papillomavirus Type 33 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

This article summarizes several clinical trials investigating the use of the 9-valent human papillomavirus (HPV) vaccine, also known as Gardasil 9, for preventing and treating various HPV-related conditions. The trials explore the vaccine’s efficacy in different populations and scenarios, including extended dosing intervals in adolescents, immunocompromised patients, adults with oral HPV infection, women with vulvar or cervical lesions, and patients with difficult-to-treat warts. These studies aim to expand our understanding of the vaccine’s potential benefits beyond its current approved uses.

Table of Contents

What is the HPV Type 33 L1 Protein Vaccine?

The Human Papillomavirus (HPV) Type 33 L1 Protein vaccine is part of a 9-valent HPV vaccine called Gardasil 9. This vaccine contains proteins from nine different HPV types, including type 33, to protect against HPV infection and related diseases.[1]

Specifically, the vaccine contains the L1 protein from HPV type 33, which is produced using recombinant DNA technology in yeast cells. The L1 protein forms virus-like particles that mimic the HPV virus but do not contain genetic material, so they cannot cause infection.[1]

How Does It Work?

The vaccine works by stimulating the body’s immune system to produce antibodies against the HPV L1 proteins. When a person is later exposed to the real virus, their immune system recognizes it and can quickly mount a response to prevent infection.[1]

The vaccine is adsorbed, meaning the proteins are attached to an aluminum-containing compound that helps boost the immune response.[1]

What Does It Treat and Prevent?

The HPV Type 33 L1 Protein vaccine, as part of Gardasil 9, helps prevent:

  • Persistent anogenital HPV infection
  • Cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
  • Genital warts caused by HPV types 6 and 11
  • Precancerous lesions like cervical intraepithelial neoplasia (CIN) and vulvar high-grade squamous intraepithelial lesions (vHSIL)[2][3]

How is It Administered?

The vaccine is given as an intramuscular injection, typically in the upper arm or thigh. The standard dosing schedule includes:

  • 3 doses for individuals 15 years and older: at 0, 2, and 6 months
  • 2 doses for children 9-14 years old: at 0 and 6-12 months apart[1][1]

Some ongoing studies are investigating extended dosing intervals and their impact on vaccine efficacy.[1]

Effectiveness

Clinical trials have shown that the 9-valent HPV vaccine, which includes the Type 33 L1 Protein, is highly effective in preventing HPV infections and related diseases. The vaccine stimulates a strong immune response, with high rates of seroconversion (development of antibodies) observed in study participants.[1]

Ongoing research is evaluating the vaccine’s effectiveness in various populations, including immunocompromised individuals and adult males.[4][5]

Safety and Side Effects

The HPV Type 33 L1 Protein vaccine has been extensively tested and is considered safe. Common side effects may include:

  • Pain, swelling, or redness at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness[1]

Serious allergic reactions are rare but possible. Patients with a history of severe allergic reactions to vaccine components should not receive the vaccine.[1]

Who Should Get the Vaccine?

The HPV Type 33 L1 Protein vaccine, as part of Gardasil 9, is recommended for:

  • Girls and boys aged 9-14 years (2-dose schedule)
  • Adolescents and young adults aged 15-26 years who haven’t been previously vaccinated (3-dose schedule)
  • Some adults aged 27-45 years may benefit from vaccination after discussing with their healthcare provider[1][1]

The vaccine is not recommended for pregnant women or individuals with severe allergies to vaccine components.[1]

Ongoing Research

Several clinical trials are currently investigating the HPV Type 33 L1 Protein vaccine (as part of Gardasil 9) in various contexts:

  • Extended dosing intervals in children and adolescents[1]
  • Effectiveness in immunocompromised children and adolescents[4]
  • Prevention of oral HPV infections in adult males[5]
  • Use as adjuvant therapy in women treated for high-grade cervical lesions or early cervical cancer[6]
  • Effectiveness in treating difficult-to-treat palmar or plantar warts[7]

These studies aim to expand our understanding of the vaccine’s potential benefits and optimize its use in different populations.

Trial Focus Population Key Objectives Potential Impact
Extended dosing intervals Boys and girls 9-14 years old Evaluate safety and immunogenicity of 2-dose regimens with extended intervals Optimize vaccination schedule for improved compliance and coverage
Immunocompromised patients Children and adolescents with compromised immune systems Assess immunogenicity and identify markers of immune response Improve protection for vulnerable populations
Oral HPV prevention Adult males 20-45 years old Evaluate efficacy in preventing oral persistent HPV infection Expand vaccine benefits to reduce oral HPV-related diseases
Vulvar HSIL treatment Women with vulvar high-grade squamous intraepithelial lesions Assess efficacy in preventing recurrence after treatment Improve management of vulvar precancerous lesions
Cervical lesion treatment Women over 45 with high-grade cervical lesions Evaluate impact on recurrence and HPV clearance after LEEP Enhance post-treatment outcomes for cervical precancer
Resistant wart treatment Patients with difficult-to-treat palmar or plantar warts Assess efficacy in treating resistant warts Develop new therapeutic approach for persistent HPV infections

FAQ

  • What is the 9-valent HPV vaccine? The 9-valent HPV vaccine, also known as Gardasil 9, is a vaccine that protects against nine types of human papillomavirus (HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58). It is designed to prevent HPV-related diseases such as cervical, vulvar, vaginal, and anal cancers, as well as genital warts.
  • Who are the target populations for these clinical trials? The clinical trials target various populations, including adolescents aged 9-14, immunocompromised children and adolescents, adult males aged 20-45, women with vulvar or cervical lesions, and patients with difficult-to-treat palmar or plantar warts. Each trial focuses on a specific group to evaluate the vaccine's effectiveness in different scenarios.
  • What are the main objectives of these clinical trials? The main objectives of these trials include evaluating the vaccine's safety and immunogenicity with extended dosing intervals, assessing its efficacy in preventing oral HPV infections, studying its impact on recurrence of vulvar or cervical lesions, and investigating its potential in treating resistant warts. The studies aim to expand the vaccine's applications and optimize its use in various clinical settings.
  • How is the vaccine administered in these trials? In most trials, the vaccine is administered as a series of intramuscular injections. The number of doses and intervals between injections may vary depending on the specific trial protocol. For example, some trials compare 2-dose regimens with extended intervals to the standard 3-dose regimen, while others follow the typical 3-dose schedule over 6 months.
  • What are the potential benefits of these clinical trials? These clinical trials may lead to expanded indications for the 9-valent HPV vaccine, improved vaccination strategies for different populations, and new therapeutic applications. Potential benefits include better protection against HPV-related diseases, reduced recurrence of pre-cancerous lesions, and novel treatment options for persistent HPV infections and related conditions. The results could inform future vaccination policies and clinical practice guidelines.

Ongoing Clinical Trials on Human Papillomavirus Type 33 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

Glossary

  • HPV (Human Papillomavirus): A group of viruses that can cause various types of cancer and genital warts. There are many different types of HPV, some of which are targeted by the 9-valent vaccine.
  • 9-valent HPV vaccine: A vaccine that protects against nine types of HPV (6, 11, 16, 18, 31, 33, 45, 52, and 58), also known as Gardasil 9.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent, indicating an immune response to vaccination or infection.
  • CIN (Cervical Intraepithelial Neoplasia): Abnormal cell growth on the surface of the cervix that may progress to cervical cancer if left untreated.
  • HSIL (High-grade Squamous Intraepithelial Lesion): A precancerous condition characterized by abnormal cell growth on the surface of the cervix or vulva.
  • LEEP (Loop Electrosurgical Excision Procedure): A surgical procedure used to remove abnormal tissue from the cervix using a thin wire loop heated by electric current.
  • Conization: A surgical procedure to remove a cone-shaped piece of tissue from the cervix for diagnostic or treatment purposes.
  • Persistent infection: An infection that continues for an extended period, often defined as lasting 6 months or longer in the context of HPV.
  • Recurrence: The return of a disease or condition after a period of improvement or remission.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2023-506792-94-00
  3. http://clinicaltrials.eu/trial-id/2024-513081-19-00
  4. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  5. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  6. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-hpv-9-valent-vaccine-in-women-undergoing-leep-for-high-grade-cervical-lesions-or-early-cervical-cancer/
  7. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-the-nonavalent-hpv-vaccine-in-treating-hard-to-treat-palmar-or-plantar-warts-in-patients-who-have-not-responded-to-two-previous-treatments/